Author: Hanju Lee

Student Ventures

A New Space for Student Entrepreneurs near the Homewood…

A New Space for Student Entrepreneurs near the Homewood campus

Johns Hopkins University students now have a new space in Remington to help grow ideas, inventions, startups, crafts, robotics and more into reality.

Located on 29th Street across from R. House, the new 10,000 square foot facility include co-working space, conference rooms and large common areas for gatherings and events as well as makerspace.

“This is not just a place for founders. It’s meant for anybody who wants to solve problems,” JHTV’s Director of Student Ventures Kerrie Carden recently told Baltimore.

Since 2016, FastForward U has been providing training and resources to empower emerging student entrepreneurs to develop ideas and disruptive technologies into successful startups. The opening of a space, though, reflects a strategic university commitment to encourage all students to learn through entrepreneurial thinking and real world problem solving.

Kerrie Carden, JHTV’s Director of Student Ventures, said the space aims to provide resources for students creating a startup, social enterprise or nonprofit at any level, from the “curious to committed.”

From cloud-based pathology platforms and custom manufacturing technologies to fashionable backpacks for photographers and online recruiting platforms, Johns Hopkins students develop an array of promising technologies and products inside and with the support of these student spaces.

The opening of FastForward U Homewood has created a buzz this Fall. Read more about this milestone in the Hub and Baltimore.

To view photos of the FastForward U Homewood Grand Opening event click here.

Corporate Collaborations

Bluefield Innovations Welcomes Vincent Kalish as Chief Scientific Officer

Bluefield Innovations Welcomes Vincent Kalish as Chief Scientific Officer


As the chief scientific officer for Bluefield Innovations, Dr. Vincent J. Kalish, Ph.D., will work closely with Johns Hopkins investigators, the Bluefield Joint Steering Committee and Deerfield Management drug development experts to catalyze the development of early stage therapeutics.

Bluefield Innovations is an innovative collaboration between The Johns Hopkins University and Deerfield Management that is dedicated to navigating the complexities of scientific advancement from concept to commercialization. Funded by Deerfield Management, Bluefield Innovations is providing up to $65 million over five years to support the commercialization of early stage therapeutic research at Johns Hopkins.

“Vince has the knowledge, experience and demeanor to bring the innovative projects on the Johns Hopkins campus to market in an efficient and professional manner,” said Dr. Brian Bizoza, partner on the Pharmaceutical team at Deerfield Management and a Johns Hopkins University alumnus

Kalish says that he was attracted to the opportunity to help the research groups at Johns Hopkins “get through the difficult translation phase from laboratory result to clinical development.”

“We see multiple projects being funded out of the amazing research at Johns Hopkins and eventually multiple companies being spun out, making a difference for patients and researchers,” Kalish said.

Bluefield Innovations is currently funding a cancer project with Dr. Marikki Laiho and expects to soon fund additional projects.

Kalish is well suited for the job as a seasoned drug hunter with extensive experience in the preclinical development of drug candidates, medicinal chemistry, patents and project leadership during 30 years in the biopharma industry. Prior to joining Bluefield, Kalish was a founder and senior vice president of chemistry and pre-clinical development for Revivo Therapeutics and a consultant for multiple startup biotech ventures. He has also held leadership roles with Cardioxyl Pharmaceuticals and Guilford Pharmaceuticals, which both had ties to Johns Hopkins.

Kalish is also an inventor on 43 issued U.S. patents and a co-inventor of multiple compounds that have advanced into Investigational New Drug and Phase 1 and Phase 2 clinical trials including Viracept, the marketed HIV protease inhibitor. Kalish earned a Ph.D. in organic chemistry from Penn State University and a B.S. from Rutgers University.

He admits that science is not his only interest. “I have been a water person all my life,” he said. “I love racing and cruising sailboats with friends and family.”

The next round of proposal submissions will open on October 15 and close November 15. For more details please visit the Bluefield website.

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien